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INTERACTION BETWEEN FK506 AND CLOTRIMAZOLE IN A LIVER TRANSPLANT RECIPIENT' 
FK506, a new and powerful immunosuppressant, has become 
the principal drug in the immunosuppressive regimens of organ 
transplant recipients at the University of Pittsburgh (1-3). It 
is well known that transplant patients often receive multiple-
drug therapy, and that many of these co-administered agents 
can alter the kinetics of immunosuppressive drugs, such as 
cyciosporine and prednisone (4,5). In this communication we 
report for the first time a potential interaction between FK506 
and the antifungal agent ciotrimazole in a liver transplant 
recipient. 
The recipient, a 55-year-old male received a liver transplant, 
on November 28, 1989, at the Veterans Affairs Medical Center 
of Pittsburgh, for chronic non-A-non-B hepatitis. His immu-
nosuppressive regimen consisted of FK506 and prednisone, and 
after uneventful recovery he was discharged on the 15th post-
operative day. On the 84th posttransplant day, he was read-
mitted with hyperglycemia, elevated liver function tests, mild 
elevation of the serum creatinine, and oropharyngeal moniliasis 
despite prophylactic nystatin therapy. The trough plasma 
FK506 concentration, 24 hr after admission. was 3.5 ng/ml. 
Since his liver biopsy disclosed mild lobular hepatitis, both his 
FK506 and steroid doses were decreased. The carbohydrate 
metabolism improved, but his serum creatinine and FK506 
levels continued to rise in spite of a dose reduction (Fig. 1). 
Since the increase in plasma FK506 concentration could not 
be solely attributed to the mild hepatic dysfunction, a drug 
interaction with clotrimazole was suspected, since this drug, 
started on the 88th posttransplant day, was the only new 
medication added to the patient's therapy. 
Although cytomegalovirus was never isolated from the liver, 
it was found in the patient's huffy coat, stomach mucosa, and 
urine. He received gancyclovir from the 99th to the 112th 
posttransplant day and was discharged on the 114th posttrans-
plant day, with normal fasting blood sugar, a serum creatinine 
of 2.0 mg/dl, and normal liver biochemistry. 
Two pharmacokinetic studies were performed after the pa-
tient had been placed on a fixed dose of FK506 (6 mg once a 
day). The first study was carried out on the 103rd posttrans-
plant day, 15 days after starting clotrimazole therapy (10 mg 
4 times a day). The second study was performed on the 107th 
posttransplant day, 4 days after discontinuation of clotrimazole 
therapy (Fig. 1). In order to reconfirm the drug interaction, 
clotrimazole was restarted the day after the second kinetic 
study for 5 days, and daily FK506 concentrations were moni-
tored (Fig. 1). On the study days, multiple blood samples (11) 
were collected just prior to the oral FK506 dose and at various 
time periods for the next 24 hr. Blood samples were incubated 
at 37°C for 30 min and centrifuged at 37°C to separate the 
plasma. Plasma samples were frozen at -70"C and analyzed 
for FK506, within a week, using an ELISA assay (6). 
As seen in Figure 1, prior to adding the clotrimazole, the 
trough plasma FK506 concentrations increased from 0.7 ng/ml 
to 3.5 ng/ml. This was probably due to mild hepatic dysfunc-
tion. The addition of clotrimazole further increased the trough 
levels to 5.6 ng/ml in a day and to greater than 9.0 ng/ml 
within 8 days. 
'This work was supported by research grants from the Veterans 
Administration and Project Grant No. DK 29961 from the National 
Institutes of Health. Bethesda. Maryland. 
The pharmacokinetic studies (Fig. 2) revealed a twofold 
increase in the area under the plasma concentration versus 
time curve (AUC) of FK506 in the presence of clotrimazole, as 
compared with the AUC in the absence of clotrimazole. The 
half-life of FK506 did not appear to be significantly different 
in the presence (10.5 hr) and in the absence of clotrimazole 
(11.8 hr). Reinitiation of clotrimazole therapy for 5 days after 
the kinetic study disclosed again an increase in FK506 concen-
tration in the presence of clotrimazole. 
Clotrimazole (Myceiex troches), an imidazole antifungal, is 
occasionally used for the treatment and/or prophylaxis of mu-
cocutaneous candidiasis. In spite of being poorly and erratically 
absorbed, it is suspected that clotrimazole can interact with 
other medications that are metabolized through the same P-
450 enzymatic system of the liver, leading to an increased half-
life of drugs such as cyclosporine (5). However, the pharma-
cokinetics studies performed in this patient disclosed an in-
creased plasma concentration of the FK506 in the presence 
clotrimazole, without any change in the half-life. The exact 
mechanism of this interaction is not completely clear at the 
present time. One possible explanation is that the intestinal 
metabolism of FK506 may be reduced in the presence of clotri-
mazole. Recent evidence has suggested: (1) that there is abun-
dant cytochrome P-450 in the enterocytes of the human jejunal 
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FIGURE 1. Patient's serial biochemistries, trough FK506 plasma 
concentrations and FK506 dose, from posttransplant day 73 to post-
transplant day 118. The shadowed areas correspond to the period of 
time during which the patient received Clotrimazole therapy, and the 
arrows indicate the dates during which the pharmacokinetics studies 
were performed. 
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FIGURE 2. Patient's FK506 pharmacokinetic profile with clotrima· 
zole (continuous line) and without clotrimazole (interrupted line). 
AUC: area under the curve. 
mucosa (7); (2) that there is metabolism of FK506 (8) and of 
cyclosporine (9), in the intestinal microsomes; and (3) that 
drug interactions in the intestine can lead to altered kinetics 
of drugs, as is the case of cyclosporine in the presence of 
erythromycin (10). Therefore, it is conceivable, that since most 
of the clotrimazole from the troche eventually reach the intes-
tine, it can compete with FK506 for the binding sites of P·450 
enzymatic system. thereby decreasing the amount of FK506 
metabolized by the intestinal mucosa and increasing the 
amount of drug available for absorption. On the other hand. 
clotrimazole to a certain extent could also decrease the hepatic 
P·450 enzymes responsible for FK506 metabolism, without 
significantly affecting the half-life of the drug. Independent of 
the mechanism involved, it is clear that coadministration of 
clotrimazole with FK506 causes an increase in the FK506 
concentrations, and that the dose of the latter has to be reduced 
in such cases, to avoid toxicity. Finally, as already noted with 
cyclosporine and diltiazem, this interaction could be useful in 
reducing the dose of FK506 required to achieve a desired FK506 
therapeutic concentration. 
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THE EFFECT OF MEAL COMPOSITION ON CYCLOSPORINE ABSORPTIONl 
Determination of factors that influence cyciosporine (CsA) 
pharmacokinetics is important for the optimal dosing of this 
agent in transplant recipients. Food is known to alter the 
absorption of many medications (1). CsA's properties of high 
lipophiiicity, the importance of bile for absorption (2), and 
zero-order absorption (3, 4) suggest that food has the potential 
1 This work was supported by grants from the Kidney Foundation of 
Canada. Manitoba Branch. and the Health Sciences Centre Clinical 
Pharmacy Research Fund. 
to alter its absorption. Considering the lipid solubility of CsA. 
a meal high in fat may increase its absorption. Given the narrow 
therapeutic index for CsA, alterations in CsA absorption could 
have significant clinical implications. 
Data on the effect of food on CsA absorption are conflicting 
(5-13). Seven studies demonstrate either no significant change 
(5-10) or a decrease (J 1) in CsA absorption parameters. A 
significant increase in CsA absorption with food has been 
observed in two studies. one in renal transplant patients (12) 
and the other in healthy volunteers (13). Previous studies have 
